JP5792630B2 - Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 - Google Patents

Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Download PDF

Info

Publication number
JP5792630B2
JP5792630B2 JP2011546814A JP2011546814A JP5792630B2 JP 5792630 B2 JP5792630 B2 JP 5792630B2 JP 2011546814 A JP2011546814 A JP 2011546814A JP 2011546814 A JP2011546814 A JP 2011546814A JP 5792630 B2 JP5792630 B2 JP 5792630B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
sequence
peptide
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011546814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516140A (ja
JP2012516140A5 (enExample
Inventor
ダル ディガン フローレンス
ダル ディガン フローレンス
ジェイ．ニューマン マーク
ジェイ．ニューマン マーク
エル．アレキサンダー ジェフリー
エル．アレキサンダー ジェフリー
スコット　サウスウッド
サウスウッド スコット
Original Assignee
エピミューン，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピミューン，インコーポレイティド filed Critical エピミューン，インコーポレイティド
Publication of JP2012516140A publication Critical patent/JP2012516140A/ja
Publication of JP2012516140A5 publication Critical patent/JP2012516140A5/ja
Application granted granted Critical
Publication of JP5792630B2 publication Critical patent/JP5792630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011546814A 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用 Active JP5792630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14789209P 2009-01-28 2009-01-28
EP09151495 2009-01-28
US61/147,892 2009-01-28
EP09151495.0 2009-01-28
PCT/EP2010/050839 WO2010086294A2 (en) 2009-01-28 2010-01-26 Pan-dr binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2012516140A JP2012516140A (ja) 2012-07-19
JP2012516140A5 JP2012516140A5 (enExample) 2013-03-14
JP5792630B2 true JP5792630B2 (ja) 2015-10-14

Family

ID=42025833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546814A Active JP5792630B2 (ja) 2009-01-28 2010-01-26 Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用

Country Status (4)

Country Link
US (2) US9249187B2 (enExample)
EP (1) EP2391635B1 (enExample)
JP (1) JP5792630B2 (enExample)
WO (1) WO2010086294A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2014296038B2 (en) 2013-07-31 2020-09-10 Bioventures, Llc. Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CN109748952B (zh) * 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
US11097002B2 (en) * 2018-06-13 2021-08-24 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US20220383996A1 (en) 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
MX2024010450A (es) 2022-02-28 2024-09-18 Tridem Bioscience Gmbh & Co Kg Conjugado que consiste de o que comprende al menos un beta-glucano o un manano.
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
DE69231621T2 (de) 1991-08-26 2001-05-31 Epimmune, Inc. Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons
DK0534618T3 (da) 1991-08-26 2006-07-24 Scripps Research Inst Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
CA2141960A1 (en) 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
KR960700745A (ko) 1993-02-26 1996-02-24 더글라스 에이. 빙햄 비(b)형 간염 바이러스에 대한 세포독성 티(t) 임파세포 응답반응을 유도하는 펩티드(peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus)
EP0703783B1 (en) * 1993-03-05 2010-05-05 Epimmune Inc. Methods of making immunogenic hla-a2.1 binding peptides
WO1994026774A1 (en) 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
AU702367B2 (en) 1993-08-02 1999-02-18 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
AU702517B2 (en) 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5554724A (en) 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
AU6103896A (en) 1995-06-07 1996-12-30 Cytel Corporation Manufacture and purification of peptides
WO1997026784A1 (en) 1996-01-24 1997-07-31 Cytel Corporation Induction of immune response against desired determinants
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
BR9708220A (pt) 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
WO2004089973A2 (en) 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
EP1012238A4 (en) 1997-01-31 2003-03-05 Epimmune Inc PEPTIDES AND ANTIQUE PRESENTING CELLS LOADED WITH PEPTIDES FOR THE ACTIVATION OF CYTOTOXIC T CELLS
DK1447414T3 (da) 1997-10-10 2007-09-10 Us Gov Health & Human Serv Antagonistpeptider af carcinoembronisk antigen (CEA)
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PEPTIDES AND THEIR APPLICATIONS
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
CA2332786A1 (en) * 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
CA2330824A1 (en) 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
EE200100203A (et) 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
WO2000044775A2 (en) 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1225907A4 (en) 1999-10-05 2005-06-22 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
EP1237564A4 (en) 1999-12-10 2005-05-04 Epimmune Inc TRIGGERING OF CELLULAR IMMUNE RESPONSES AGAINST P53 USING NUCLEIC ACID AND PEPTIDE COMPOSITIONS
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2003530083A (ja) 1999-12-10 2003-10-14 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
US20040146519A1 (en) 1999-12-10 2004-07-29 John Fikes Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
EP1235841A4 (en) 1999-12-10 2006-04-12 Epimmune Inc TRIGGERING MAGE2 / 3 CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
US20040037843A1 (en) 1999-12-21 2004-02-26 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
JP2004512815A (ja) 1999-12-28 2004-04-30 エピミューン　インコーポレイテッド 最適化されたミニ遺伝子およびそれによってコードされるペプチド
AU2000232427A1 (en) 2000-02-23 2001-09-03 Epimmune Inc. HLA binding peptides and their uses
EP1320377B1 (en) 2000-09-01 2011-03-23 Epimmune Inc. Hla binding peptides and their uses
EP1313505A4 (en) 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
AU2000275748A1 (en) 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
JP2004508320A (ja) 2000-09-08 2004-03-18 エピミューン　インコーポレイテッド ペプチドおよび核酸組成物を用いるｂ型肝炎ウイルスに対する細胞性免疫応答の誘導
WO2003087126A2 (en) 2002-04-05 2003-10-23 Epimmune Inc. Heteroclitic analogs and related methods
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
AU2003287019B2 (en) 2002-10-03 2010-07-22 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US8017745B2 (en) 2002-12-06 2011-09-13 Epimmune Inc. Plasmodium falciparum antigens and methods of use
EP1583548A4 (en) 2002-12-10 2007-10-17 Epimmune Inc HLA-A1, A2 -A3, -A24, -B7 AND B44TUMOR ASSOCIATED ANTIGENPEPTIDES AND COMPOSITIONS
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
PL1620456T3 (pl) 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2008509654A (ja) 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
US20090317412A1 (en) 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
AU2007314550A1 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides
WO2008039267A2 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9910646B2 (en) 2015-12-26 2018-03-06 Intel Corporation Technologies for native code invocation using binary analysis

Also Published As

Publication number Publication date
WO2010086294A3 (en) 2010-11-25
US20110293646A1 (en) 2011-12-01
JP2012516140A (ja) 2012-07-19
US20160114035A1 (en) 2016-04-28
EP2391635B1 (en) 2017-04-26
WO2010086294A2 (en) 2010-08-05
US9249187B2 (en) 2016-02-02
US9789181B2 (en) 2017-10-17
EP2391635A2 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
JP5792630B2 (ja) Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
US6413935B1 (en) Induction of immune response against desired determinants
EP2247306B1 (en) Immunogenic control of tumours and tumour cells
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
JP4063879B2 (ja) 所望の決定基に対する免疫応答の誘導
EP0907370B1 (en) Hla-a2.1 binding peptides and their uses
US20220273790A1 (en) Rationally engineered carrier proteins for vaccines
CA2386341A1 (en) Heteroclitic analogs and related methods
JPH03173830A (ja) ワクチン組成物
JP2010535026A (ja) 多量体マルチエピトープインフルエンザワクチン
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
US20050049197A1 (en) Induction of immune response against desired determinants
WO2021231441A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
Gras-Masse Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations
WO2010027973A1 (en) Human papillomavirus / li-key hybrids and methods of use
US20230134067A1 (en) A peptide used for immunotherapeutics
US20150203830A1 (en) Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
US20250332246A1 (en) Enhanced expression via autotransporters
US20260001938A1 (en) Peptide used for immunotherapeutics
CN100368436C (zh) 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法
Wijayadikusumah An evaluation of charged Pam2Cys-based lipopeptides as novel adjuvants for subunit-based vaccines
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
CN116528882A (zh) 用于免疫治疗剂的肽
CN1913918A (zh) 用作免疫佐剂的gm1结合缺陷的外毒素

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150806

R150 Certificate of patent or registration of utility model

Ref document number: 5792630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250